

PRESS RELEASE

EOS imaging Announces the Opening of the First EOS® Site in South Korea

Konyang University Hospital will pioneer low dose 2D/3D imaging in the large South Korean market

Paris, November 28, 2016 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today the official opening of the first EOS site in South Korea, the third largest market in Asia, at the Konyang University Hospital. The University Hospital serves an adult and pediatric population of over 1 million outpatients and over 250,000 inpatients on average per year.

The University Hospital has a strong orthopedics department for surgical and non-surgical treatment of the spine and joints. Patients of the specialized spine clinic will benefit from the low dose, full body images and weight-bearing, 3D analysis that EOS provides for deformative and degenerative spine conditions. In addition, the joint replacement clinic will use the EOS images and 3D torsion and alignment measurements to improve the planning of arthroplasty surgeries and control post-operative outcomes.

Prof Kim Sang Beom, Chief of the Spine Centre and Orthopedics Department and Board Member of the Korea Spine Surgeon Association, commented, *“EOS is a real innovative technology with low dose biplanar 2D/3D radiography that’s approved by NECA. We are happy to be able to extend our services and care to our patients with this technology, including beginning to screen children and students utilizing the applicable Micro Dose option. The Konyang University Hospital uses the most advanced technology for better patient outcome. EOS will be the gold standard for musculoskeletal treatment in the near future.”*

Marie Meynadier, CEO of EOS imaging, commented, *“The Konyang University Hospital will be a strong reference center for the EOS platform in South Korea. Together with the Innovative Technology status obtained from the NECA Center for New Health Technology earlier this year, this will fuel adoption in the important South Korean market. We look forward to serving more Korean hospitals, healthcare professionals and patients with our low dose 2D/3D technology.”*

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext® PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

**About EOS imaging**

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States, Japan, China, and the European Union. The Group posted 2015 revenues of €21.8 million and employs 122 people. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.



PRESS RELEASE

Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Valentine Brouchet

Ph: +33 (0)1 44 71 94 96

eosimaging@newcap.eu

The Ruth Group (US)

Press relations / Joanna Zimmerman

Ph: 646-536-7006

jjzimmerman@theruthgroup.com